Pharmaceutical composition comprising 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and sodium ions
A letermovir and sodium ion composition with a specific molar ratio and absence of complexing solubilizers provides stable, ready-to-use solutions for treating HCMV infections, addressing the need for long-term stability and ease of administration in diverse patient groups.
Patent Information
- Application Number
- JP2022551669
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-02-27
- Filing Date
- 2021-03-01
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-03-01
AI Technical Summary
There is a need for pharmaceutical compositions containing letermovir that exhibit long-term stability at physiological pH and are suitable for use in subjects of all ages, particularly those undergoing solid organ transplantation or allogeneic hematopoietic stem cell transplantation, without the use of complexing solubilizing agents like PEG, lysine, arginine, and cyclodextrin, which can cause particle formation and require additional filtration before administration.
A pharmaceutical composition comprising letermovir and sodium ions in a specific molar ratio, ranging from 0.50 to 1.00, preferably 0.80 to 0.90, that achieves a pH of 7 to 8 and is free of complexing solubilizers, allowing for a ready-to-use, particle-free solution that can be lyophilized and redissolved in parenterally acceptable diluents.
The composition maintains long-term stability and physiological pH, ensuring effective therapeutic delivery without the need for additional solubilizers, and can be easily reconstituted for use in various diluents, suitable for treating viral infections such as human cytomegalovirus (HCMV) in diverse patient populations.
Smart Images

Figure 0007590444000001 
Figure 0007590444000002 
Figure 0007590444000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel stable pharmaceutical composition containing 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid, also known as letermovir, suitable for oral and intravenous administration and injection, and sodium ions. The pharmaceutical composition is essentially free of certain complexing solubilizing agents, such as PEG, cyclodextrin, lysine, arginine, and especially HPBCD. The formulation is suitable for use in a method for treating viral diseases, particularly human cytomegalovirus (hereinafter HCMV) infection. The present invention also relates to a method for preparing the pharmaceutical composition. [Background technology]
[0002] Cytomegalovirus (CMV) is a common opportunistic infection that causes significant morbidity and preventable mortality after solid organ transplantation and allogeneic hematopoietic stem cell transplantation.
[0003] HCMV is a type of virus that belongs to the family of viruses known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV and alternatively known as human herpesvirus 5 (HHV-5). Within the Herpesviridae family, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals.
[0004] Letermovir is known as a highly active drug for combating HCMV infection and has been described in detail in Lischka et al., In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound Letermovir. Antimicrob. Agents Chemother. 2010, 54: p. 1290-1297, and Kaul et al., First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound Letermovir. Am. J. Transplant. 2011, 11: 1079-1084, as well as Marschall et al., In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound Letermovir against Herpesviruses and Other Human Pathogenic Viruses. Antimicrob. Agents Chemother. 2012, 56: 1135-1137.
[0005] The correct chemical name of letermovir is 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid, and the chemical structure of letermovir is shown below. [ka]
[0006] Letermovir has been developed as an antiviral agent, particularly for the treatment, prevention, or prophylaxis of infections caused by human cytomegalovirus (HCMV), and is disclosed in WO 2004 / 096778. Additionally, salts of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid have also been prepared, as described in WO 2013 / 127971.
[0007] A liquid pharmaceutical formulation comprising amorphous letermovir is described in WO 2013 / 127970, which formulation in particular relates to a pharmaceutical composition that can be used for intravenous administration, contains letermovir, has long-term stability, is storable, and has a substantially physiological pH. It has further been discovered that such compositions can be lyophilized to obtain a stable solid pharmaceutical composition that can be redissolved in a simple manner for injection, for example by adding water, resulting in a stable pharmaceutical composition for, for example, intravenous administration.
[0008] However, there remains a need for a pharmaceutical composition comprising letermovir with long-term stability at substantially physiological pH, suitable for use in subjects of all ages who require solid organ transplantation and allogeneic hematopoietic stem cell transplantation. Moreover, pharmaceutical compositions comprising letermovir and complexed solubilizers, such as PEG, lysine, arginine, cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD), tend to cause particle problems when dissolved in parenterally acceptable diluents such as water, and therefore require additional work-up prior to intended use, such as filtration of the pharmaceutical composition prior to administration. Thus, there remains a need for a ready-to-use, particle-free parenteral solution comprising letermovir. Summary of the Invention
[0009] In a first aspect, the present invention provides a pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.50-<1.00:1.00, preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00; the pharmaceutical composition can exhibit a pH in the range of 7 to 8 when dissolved in water at a concentration of 1 to 100 mg / mL of letermovir; Essentially free of complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD). It relates to pharmaceutical compositions.
[0010] At a molar ratio of sodium ion to letermovir of 0.50-<1.00:1.00, preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, letermovir exhibits improved solubility and is present in sufficient concentrations to achieve the desired therapeutic effect without the need for additional solubilizing agents, particularly complexing solubilizing agents such as cyclodextrins, and pharmaceutical compositions containing sodium ion at said ratios have a substantially physiological pH and exhibit long-term stability.
[0011] It has further been found that the pharmaceutical composition can be obtained in the form of a lyophilisate which can be completely redissolved in parenterally acceptable diluents such as water, aqueous glucose or lactated Ringer's solution. When redissolved, the lyophilisate exhibits a pH in the range of 7-8, preferably 7.4-7.8, when letermovir is present in the reconstituted solution in a concentration range of 1-100 mg / mL, preferably 20-100 mg / mL. The pH of the reconstituted solution is stable in the molar ratio of sodium ions to letermovir in the range of 0.50-<1.00:1.00, preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, and is in the physiological range of 7-8, preferably 7.4-7.8, a clear evidence of the surprising self-buffering action of sodium ions in the given range. The resulting reconstituted solution exhibits long term stability.
[0012] In another aspect, the present invention relates to a method for producing said pharmaceutical composition comprising the steps of: i) providing a solution of letermovir and sodium ions, the molar ratio of letermovir to sodium ions being in the range of 0.50-<1.00:1.00, preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, particularly 0.84-0.88:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, such as sucrose or mannitol, amino acids, such as phenylalanine, polyalkoxy compounds, such as poloxamers, particularly poloxamer 188, and polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i) to a value in the range of 7-8, preferably using HCl; iii) Optionally, filtering the solution.
[0013] In particular, the method according to the present invention may further comprise the subsequent steps of lyophilizing the solution obtained in step iii above to obtain a lyophilisate, optionally redissolving the lyophilisate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 1-100 mg / mL, preferably 20-100 mg / mL, with respect to letermovir, and optionally further diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, said first and said second parenterally acceptable diluents being the same or different.
[0014] Another aspect of the present invention relates to the use of a pharmaceutical composition as described herein for the preparation of a medicament for the treatment and / or prevention of a disease, in particular a viral infection, preferably a human cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group.
[0015] Another aspect of the present invention relates to a method for the treatment and / or prevention of a viral infection, preferably a human cytomegalovirus (HCMV) infection or an infection with another member of the Herpesviridae group, in a subject in need thereof by administering said pharmaceutical composition. In particular, the pharmaceutical composition according to the present invention is suitable for the treatment of newborns, subjects in need of certain solid organ transplants, such as renal compromised subjects and subjects in need of allogeneic hematopoietic stem cell transplantation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] It is noted that the term "comprising" also encompasses the meaning of "consisting of", e.g. a group of members comprising said members also encompasses a group of members consisting only of those members.
[0017] As used herein, the term "room temperature" is synonymous with the term "normal room temperature" and refers to a temperature in the range of 19° C. to 26° C. For example, "stirring at room temperature" means "stirring at a temperature in the range of 19° C. to 26° C.."
[0018] Within the scope of the present invention, the term "stability" is understood to mean not only the chemical stability of the components of the pharmaceutical composition, in particular the active substances, but also the physicochemical stability of the composition itself. In particular, the compositions according to the invention must be stable against precipitation of the constituents.
[0019] In this context, the term "stable" means that the pharmaceutical composition according to the invention contains a minimum of >90%, preferably >95%, more preferably >98% of the active substance during a storage period of at least 1 month, preferably at least 3 months, even more preferably at least 6 months, even more preferably 12 months, even more preferably 18 months and most preferably at least 36 months at 2°C-8°C, or 25°C, or 40°C, as measured according to the HPLC method of the present invention.
[0020] Cyclodextrin according to the invention is understood to include any modified or unmodified cyclodextrin, in particular selected from α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin. Examples of modified β-cyclodextrins include, in particular, hydroxyalkyl-β-cyclodextrins, such as hydroxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin or hydroxypropyl-β-cyclodextrin, alkyl-hydroxyalkyl-β-cyclodextrins, such as methyl-hydroxypropyl-β-cyclodextrin or ethyl-hydroxypropyl-cyclodextrin or sulfoalkyl-cyclodextrin. Hydroxypropyl-β-cyclodextrins are available with different degrees of substitution, in particular 2-hydroxypropyl-β-cyclodextrin, available as Cavasol® W7 HP, Cavitron® W7 HP5 and Cavitron® W7 HP7.
[0021] As used herein, the term "complexed solubilizer" refers to a compound that enhances the solubility of the active ingredient of the pharmaceutical composition of the present invention by forming a coordinate bond between said compound and the molecule of the active ingredient, i.e., by actually and detectably forming a complex with the active ingredient of the pharmaceutical composition of the present invention, particularly in aqueous solution. Non-limiting examples of complexed solubilizers include non-polymeric solubilizers such as lysine or arginine, and polymeric solubilizers such as PEG or cyclodextrin.
[0022] As used herein, the terms "parenterally acceptable diluent", "parenteral admixture diluent" and "commercially available diluent" refer to a liquid material used to dilute an active ingredient suitable for administration to a subject by a route other than topical or oral. Examples of parenteral routes include intramuscular, intravascular (including intraarterial or intravenous), intraorbital, retrobulbar, intranasal, subarachnoid, intraventricular, intraspinal, intraperitoneal, intrapulmonary, intracisternal, intraarticular, intrasternal, periocular or intralesional administration. Examples of parenterally acceptable diluents include water, aqueous glucose solution or lactated Ringer's solution. Within this application, the terms "commercially available diluent", "parenteral admixture diluent" and "parenterally acceptable diluent" have the same meaning and are used interchangeably.
[0023] As used herein, the term "carbohydrate" refers to a compound that is a polyhydroxy aldehyde or ketone, or a substance that upon hydrolysis produces such a compound. Some carbohydrates may further contain nitrogen, phosphorus, or sulfur. Examples of carbohydrates include monosaccharides, disaccharides, oligosaccharides, and polysaccharides, particularly sucrose or mannitol.
[0024] As used herein, the term "amino acid" refers to any of the 20 naturally occurring amino acids or their synthetic analogues that have unnatural side chains and include both the D and L optical isomers. Examples of amino acids include alanine and phenylalanine, among others.
[0025] As used herein, the term "polyalkoxy compound" refers to a polymeric compound in which repeating units represent an alkyl group having a straight or branched chain linked to an oxygen atom. Examples of polyalkoxy compounds include poloxamers, particularly poloxamer 188.
[0026] Within the scope of the present invention, the terms "obtained by" and "obtainable by" have the same meaning and are used interchangeably.
[0027] Within the scope of the present invention, the term "equivalent" is understood to mean "molar equivalent".
[0028] As used herein, the term "aqueous solution" refers to a liquid homogeneous mixture that contains water.
[0029] As used herein, the terms "lyophilization" and "freeze-drying" are used interchangeably and refer to a process in which a desired product containing a solvent, particularly water, is cooled to a sufficient temperature, particularly by using liquid nitrogen or cooled shelves, in which the solvent is partially or completely frozen, and the frozen solvent is further removed by one or more drying steps, particularly by removal of unbound solvent by sublimation and desorption. The terms "lyophilisate" and "lyophilized product" refer to the product obtained by freeze-drying and are used interchangeably throughout this specification.
[0030] As used herein, the terms "reconstitution" or "reconstituting" refer to the process of dissolving the lyophilisate in a diluent, preferably a parenterally acceptable diluent, especially water. A "reconstituted solution" refers to the product obtained by reconstitution.
[0031] As used herein, the term "treatment" or "treating" is defined as the application or administration of a therapeutic agent, i.e., letermovir (alone or in combination with another agent), to a subject, or to an isolated tissue or cell line derived from a subject having an HCMV infection, a symptom of an HCMV infection, or the potential for developing an HCMV infection, with the intent to cure, heal, reduce, ameliorate, alter, treat, ameliorate, or affect the HCMV infection, the symptoms of an HCMV infection, or the potential for developing an HCMV infection. Such treatments can be specifically tailored or modified based on knowledge gained from the field of pharmacogenomics.
[0032] As used herein, the terms "prevent", "preventing" or "prevention" refer to the absence of onset of a disorder or disease in cases where there has been no onset of the disorder or disease, or the absence of further progression of the disorder or disease in cases where there has already been onset of the disorder or disease. Also considered is the ability to prevent some or all of the symptoms associated with a disease or disease. Prevention of a disease encompasses prophylaxis of a disease.
[0033] As used herein, the term "subject" refers to a human or non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, feline, canine, and murine mammals. Preferably, the subject is a human. In one embodiment, the subject is a human infant. In a preferred embodiment, the subject is a human newborn. In another preferred embodiment, the subject is a subject in need of a particular solid organ transplant, such as a subject with renal impairment and a subject in need of an allogeneic hematopoietic stem cell transplant.
[0034] As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that does not destroy the biological activity or properties of the compound and is relatively non-toxic, i.e., the material may be administered to a subject without causing undesired biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0035] As used herein, the term "essentially free" refers to a content of less than 5 mole percent.
[0036] The subject of the present invention is a pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.50-<1.00:1.00, preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in water to a concentration range of 1 to 100 mg / mL, preferably 20 to 100 mg / mL, of letermovir, can exhibit a pH range of 7 to 8, preferably 7.4 to 7.8; Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD) It relates to pharmaceutical compositions.
[0037] The subject of the present invention is further a pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, at a concentration of 1-100 mg / mL, preferably 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD) It relates to pharmaceutical compositions.
[0038] The subject of the present invention is further a pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.64-<1.00:1.00, preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in lactated Ringer's solution to a concentration range of 1 to 100 mg / mL, preferably 20 to 100 mg / mL of letermovir, can exhibit a pH range of 7 to 8, preferably 7.4 to 7.8; Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD) It relates to pharmaceutical compositions.
[0039] In one embodiment, the pharmaceutical composition according to the invention is essentially free of compounds selected from the group consisting of PEG, lysine, arginine, and cyclodextrin. In one embodiment, the pharmaceutical composition according to the invention is essentially free of lysine. In another embodiment, the pharmaceutical composition according to the invention is essentially free of arginine. In yet another embodiment, the pharmaceutical composition according to the invention is essentially free of PEG. In yet another embodiment, the pharmaceutical composition according to the invention is essentially free of cyclodextrin. In a preferred embodiment, the pharmaceutical composition according to the invention is essentially free of hydroxypropyl-β-cyclodextrin. In another preferred embodiment, the pharmaceutical composition according to the invention is essentially free of PEG, lysine, arginine, and cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD).
[0040] In one embodiment, the pharmaceutical compositions according to the invention are essentially free of complexing solubilizers, in particular essentially free of PEG, lysine, arginine, and cyclodextrins, in particular hydroxypropyl-β-cyclodextrin (HPBCD).
[0041] In one embodiment, the content of complexed solubilizer in the pharmaceutical composition according to the invention is less than 5 mol%. In a preferred embodiment, the content of complexed solubilizer in the pharmaceutical composition according to the invention is less than 3 mol%. In a more preferred embodiment, the content of complexed solubilizer in the pharmaceutical composition according to the invention is less than 1 mol%. In a more preferred embodiment, the content of complexed solubilizer in the pharmaceutical composition according to the invention is less than 0.5 mol%. Most preferably, the content of complexed solubilizer in the pharmaceutical composition according to the invention is less than 0.3 mol%.
[0042] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.50 to <1.00:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 1 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0043] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 1 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0044] In a preferred embodiment, the pharmaceutical composition according to the present invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 1 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0045] In a more preferred embodiment, the pharmaceutical composition according to the present invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.84-0.88:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 1 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0046] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.50 to <1.00:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0047] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0048] In a preferred embodiment, the pharmaceutical composition according to the present invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0049] In a more preferred embodiment, the pharmaceutical composition according to the present invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.84-0.88:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0050] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0051] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0052] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.84-0.88:1.00; the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0053] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, wherein said pharmaceutical composition comprises: sodium ions in a molar ratio relative to letermovir in the range of 0.64 to <1.00:1.00; The pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0054] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.72 to <1.00:1.00; The pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; The pharmaceutical composition according to the present invention is essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD). In one embodiment, the pharmaceutical composition according to the present invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.72-0.90:1.00; The pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0055] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.80-0.90:1.00; The pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0056] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and sodium ions, said pharmaceutical composition comprising: sodium ions in a molar ratio relative to letermovir in the range of 0.84-0.88:1.00; The pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).
[0057] In one embodiment, the pharmaceutical composition according to the present invention contains the sodium ion in a molar ratio relative to letermovir in the range of 0.50 to <1.00:1.00, preferably 0.55 to <1.00:1.00, more preferably 0.6 to <1.00:1.00, more preferably 0.64 to <1.00:1.00, more preferably 0.65 to <1.00:1.00, more preferably 0.7 to <1.00:1.00, more preferably 0.72 to <1.00:1.00, more preferably 0.74 to <1.00:1.00, more preferably 0.76 to <1.00:1.00, more preferably 0.78 to <1.00:1.00, and more preferably 0.80 to <1.00:1.00.
[0058] In one embodiment, the pharmaceutical composition according to the present invention contains the sodium ion in a molar ratio relative to letermovir in the range of 0.64 to 0.90:1.00, more preferably 0.65 to 0.90:1.00, more preferably 0.72 to 0.90:1.00, more preferably 0.80 to 0.90:1.00, more preferably 0.82 to 0.90:1.00, even more preferably 0.84 to 0.90:1.00, even more preferably 0.82 to 0.88:1.00, and most preferably 0.84 to 0.88:1.00.
[0059] In one embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir. In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir.
[0060] In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when the pharmaceutical composition is dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir. In a more preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when the pharmaceutical composition is dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir.
[0061] In one embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20 to 100 mg / mL for letermovir. In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when said pharmaceutical composition is dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20 to 100 mg / mL for letermovir.
[0062] In one embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in lactated Ringer's solution at a concentration range of 20 to 100 mg / mL of letermovir. In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when said pharmaceutical composition is dissolved in lactated Ringer's solution at a concentration range of 20 to 100 mg / mL of letermovir.
[0063] In one embodiment, there is provided a pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.50-<1.00:1.00, preferably 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 1 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; A pharmaceutical composition essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrins, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It further comprises at least one pharmaceutical carrier or excipient.
[0064] In one embodiment, there is provided a pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, at a concentration of 1-100 mg / mL, preferably 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; A pharmaceutical composition essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrins, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It further comprises at least one pharmaceutical carrier or excipient.
[0065] In one embodiment, the pharmaceutical composition comprises letermovir of formula (I) and sodium ions, [ka] sodium ions in a molar ratio relative to letermovir in the range of 0.64-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00; the pharmaceutical composition, when dissolved in lactated Ringer's solution to a concentration range of 1 to 100 mg / mL, preferably 20 to 100 mg / mL of letermovir, can exhibit a pH range of 7 to 8, preferably 7.4 to 7.8; A pharmaceutical composition essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrins, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It further comprises at least one pharmaceutical carrier or excipient.
[0066] In one embodiment, the pharmaceutical composition according to the invention comprises at least one excipient selected from the group consisting of carbohydrates such as sucrose or mannitol, amino acids such as phenylalanine, polyalkoxy compounds such as poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP) such as PVP PF12. In a preferred embodiment, said excipient is mannitol or sucrose or a combination thereof.
[0067] In one embodiment, the pharmaceutical composition according to the invention is essentially free of complexed solubilizers.
[0068] In one embodiment, the pharmaceutical composition according to the invention can contain an excipient that exhibits complexing solubilizing properties. In one embodiment, such an excipient is a polyalkoxy compound, such as a poloxamer. In one embodiment, the poloxamer is poloxamer 188.
[0069] In one embodiment, a pharmaceutical composition according to the invention comprises a polyalkoxy compound, such as a poloxamer, such as poloxamer 188, and is essentially free of other complexing solubilizing agents.
[0070] In one embodiment, the excipients used are suitable for administration to subjects in need of certain solid organ transplants, such as subjects with impaired kidneys and subjects in need of allogeneic hematopoietic stem cell transplants. Non-limiting examples of such excipients include sucrose, mannitol, phenylalanine, and poloxamers, such as poloxamer 188, and polyvinylpyrrolidone (PVP), such as PVP PF12.
[0071] In one embodiment, the pharmaceutical composition according to the invention further comprises a buffer, preferably trishydroxyaminomethane (Tris).
[0072] In one embodiment, the pharmaceutical composition according to the present invention further comprises HCl.
[0073] In one embodiment, the pharmaceutical composition according to the invention exhibits stability according to ICH Q1A(R2) (Stability testing of new drug substances and formulations) covering climatic zones I-IV. In a preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 1 month. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 3 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 6 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 12 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 18 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 36 months.
[0074] In one embodiment, the pharmaceutical composition according to the invention is in solid form. In a preferred embodiment, said solid form of said pharmaceutical composition is a lyophilisate.
[0075] In one embodiment, the pharmaceutical composition according to the invention is in liquid form. In a preferred embodiment, said liquid form of the pharmaceutical composition according to the invention is an aqueous solution. In another preferred embodiment, said liquid form of the pharmaceutical composition according to the invention is a solution in at least one parenterally acceptable diluent. Non-limiting examples of parenterally acceptable diluents include water, aqueous glucose solution and lactated Ringer's solution.
[0076] In one embodiment, a pharmaceutical composition according to the invention is suitable for intravenous (IV) administration or injection.
[0077] The subject of the present invention further relates to a method for producing a pharmaceutical composition according to the invention, comprising the following steps: i) providing a solution of letermovir and sodium ions, wherein the molar ratio of sodium ions to letermovir is in the range of 0.50 to <1.00:1.00, preferably 0.64 to <1.00:1.00, more preferably 0.65 to <1.00:1.00, more preferably 0.72 to <1.00:1.00, more preferably 0.80 to <1.00:1.00, more preferably 0.80 to 0.90:1.00, particularly in the range of 0.84 to 0.88:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, particularly sucrose or mannitol, amino acids, particularly phenylalanine, polyalkoxy compounds, particularly poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), particularly PVP PF12.
[0078] In one embodiment, the solution obtained in step i above is a solution in a parenterally acceptable diluent such as water.
[0079] In one embodiment, providing the solution according to step i above comprises the steps of: a-1) preparing a suspension of letermovir in a parenterally acceptable diluent, in particular water; b-1) adding NaOH to the suspension obtained in step a-1 to obtain a mixture; c-1) optionally stirring the mixture obtained in step b-1 for at least 30 minutes; d-1) optionally adding to said mixture at least one excipient selected from the group consisting of carbohydrates, particularly sucrose and mannitol, amino acids, particularly phenylalanine, polyalkoxy compounds, particularly poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), particularly PVP PF12; e-1) Optionally, stirring the mixture for at least 30 minutes.
[0080] In a preferred embodiment, an aqueous solution of NaOH is added in step b-1.
[0081] In a preferred embodiment, the solution in step c-1 is stirred for at least 2 hours.
[0082] In a preferred embodiment, the solution in step e-1 is stirred for at least 2 hours.
[0083] In a preferred embodiment, 0.64 to <1.00 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.65 to <1.00 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.72 to <1.00 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.80 to <1.00 equivalents of NaOH relative to letermovil are added in step b-1.
[0084] In a preferred embodiment, 0.64-0.90 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.65-0.90 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.72-0.90 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.80-0.90 equivalents of NaOH relative to letermovil are added in step b-1. In a more preferred embodiment, 0.84-0.88 equivalents of NaOH relative to letermovil are added in step b-1.
[0085] In one embodiment, 0.64 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.65 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.72 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.80 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.82 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.84 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.86 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.88 equivalents of NaOH relative to letermovil are added in step b-1. In one embodiment, 0.90 equivalents of NaOH relative to letermovir is added in step b-1.
[0086] In another embodiment, the method for preparing a solution according to step i comprises utilizing the following steps a-2 to e-2 instead of steps a-1 to e-1. a-2) Providing a solution of NaOH in a parenterally acceptable diluent, particularly water; b-2) adding letermovir to the solution obtained in step a-2 to obtain a mixture; c-2) optionally stirring the mixture obtained in step b-2 for at least 30 minutes; d-2) optionally adding to said mixture at least one excipient selected from the group consisting of carbohydrates, in particular sucrose and mannitol, amino acids, in particular phenylalanine, polyalkoxy compounds, in particular poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), in particular PVP PF12; e-2) Optionally, stirring the mixture for at least 30 minutes.
[0087] In a preferred embodiment, the solution in step c-2 is stirred for at least 2 hours.
[0088] In a preferred embodiment, the solution in step e-2 is stirred for at least 2 hours.
[0089] In a preferred embodiment, 1.56 to >1.00 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.54 to >1.00 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.39 to >1.00 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.25 to >1.00 equivalents of letermovil relative to NaOH are added in step b-2.
[0090] In a preferred embodiment, 1.56 to 1.11 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.54 to 1.11 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.39 to 1.11 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.25 to 1.11 equivalents of letermovil relative to NaOH are added in step b-2. In a more preferred embodiment, 1.19 to 1.14 equivalents of letermovil relative to NaOH are added in step b-2.
[0091] In one embodiment, 1.56 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.54 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.39 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.25 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.22 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.19 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.16 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.14 equivalents of letermovil relative to NaOH are added in step b-2. In one embodiment, 1.11 equivalents of letermovil relative to NaOH are added in step b-2.
[0092] In one embodiment, the method for producing a pharmaceutical composition according to the present invention further comprises adjusting the pH of the solution obtained in step i to a range of 7-8, preferably 7.4-7.8. In one preferred embodiment, said adjustment is performed by adding HCl. In a more preferred embodiment, the pH of the solution obtained in step i is in the range of 7-8, preferably 7.4-7.8, and no pH adjustment is required.
[0093] In one embodiment, the solution obtained after pH adjustment is optionally stirred for at least 10 minutes, preferably at least 30 minutes.
[0094] In one embodiment, the method for producing a pharmaceutical composition according to the invention optionally comprises filtering the solution obtained in step i. In one embodiment, the method for producing a pharmaceutical composition according to the invention optionally comprises filtering the solution obtained after adjusting the pH of the solution obtained in step i above.
[0095] In one embodiment, the method for producing a pharmaceutical composition according to the present invention further comprises lyophilizing the resulting solution to obtain a lyophilisate.
[0096] In one embodiment, the method for producing the pharmaceutical composition according to the present invention further comprises reconstituting the lyophilisate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 0.1-100 mg / mL with respect to letermovir, and optionally further diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion. The first and second parenterally acceptable diluents may be the same or different. In one embodiment, when letermovir is present in the reconstituted solution in the concentration range of 0.1-100 mg / mL, said reconstituted solution exhibits a pH in the range of 7-8, preferably 7.4-7.8. In a preferred embodiment, when letermovir is present in the reconstituted solution in the concentration range of 20-100 mg / mL, said reconstituted solution exhibits a pH in the range of 7-8, preferably 7.4-7.8.
[0097] In one embodiment, the final concentration acceptable for injection or injection is in the range of 0.1 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 0.8 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 20 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 50 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 20 to 50 mg / mL. In a preferred embodiment, the final concentration acceptable for injection or injection is 0.8 mg / mL.
[0098] In a preferred embodiment, the method for producing a pharmaceutical composition according to the present invention comprises the following steps: i) providing a solution of letermovir and sodium ions, the molar ratio of letermovir to sodium ions being in the range of 0.50-<1.00:1.00, preferably 0.64-<1.00:1.00, more preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, particularly in the range of 0.84-0.88:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, such as sucrose or mannitol, amino acids, such as phenylalanine, polyalkoxy compounds, such as poloxamers, particularly poloxamer 188, and polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i to a value in the range of 7 to 8, preferably 7.4 to 7.8, using suitable organic and inorganic acids; iii) Optionally, filtering the resulting solution.
[0099] In one embodiment of step ii, the organic or inorganic acid is HCl.
[0100] In another preferred embodiment, the method for producing a pharmaceutical composition according to the present invention comprises the following steps: i) providing a solution of letermovir and sodium ions, the molar ratio of letermovir to sodium ions being in the range of 0.50-<1.00:1.00, preferably 0.64-<1.00:1.00, more preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, particularly in the range of 0.84-0.88:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, such as sucrose or mannitol, amino acids, such as phenylalanine, polyalkoxy compounds, such as poloxamers, particularly poloxamer 188, and polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i to a value in the range of 7 to 8, preferably 7.4 to 7.8, using suitable organic and inorganic acids; iii) optionally filtering the resulting solution; iv) freeze-drying the resulting solution to obtain a lyophilisate.
[0101] In one embodiment of step ii, the organic or inorganic acid is HCl.
[0102] In another preferred embodiment, the method for producing a pharmaceutical composition according to the present invention comprises the following steps: i) providing a solution of letermovir and sodium ions, the molar ratio of letermovir to sodium ions being in the range of 0.50-<1.00:1.00, preferably 0.64-<1.00:1.00, more preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, particularly in the range of 0.84-0.88:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, such as sucrose or mannitol, amino acids, such as phenylalanine, polyalkoxy compounds, such as poloxamers, particularly poloxamer 188, and polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i to a value in the range of 7 to 8, preferably 7.4 to 7.8, using suitable organic and inorganic acids; iii) optionally filtering the resulting solution; iv) freeze-drying the resulting solution to obtain a lyophilisate; v) reconstituting the lyophilisate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 1-100 mg / mL, preferably 20-100 mg / mL, of letermovir, and optionally further diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, said first and second parenterally acceptable diluents being the same or different.
[0103] In one embodiment of step ii, the organic or inorganic acid is HCl.
[0104] The above steps i-v do not necessarily imply a particular order or number of steps. However, preferably, the steps of the method of the present invention are performed in the above order. Some of the steps may be optional, and in some embodiments, optional steps are not performed. For example, in one embodiment, step ii may be immediately followed by step iv without performing step iii. Also, the steps shown above do not exclude additional steps not explicitly mentioned. For example, the solution obtained in step i and / or ii may be optionally stirred.
[0105] The subject of the present invention further relates to a pharmaceutical composition obtainable by any of the methods disclosed herein.
[0106] The pharmaceutical composition according to the invention can be used for the manufacture of a medicament suitable for use in a method for the prevention and / or treatment of infections caused by representatives of the Herpesviridae group, in particular cytomegalovirus, in particular human cytomegalovirus.
[0107] Furthermore, a subject of the present invention relates to a pharmaceutical composition according to the invention for use in a method for the treatment and / or prevention of a disease, preferably a viral infection, in particular an infection caused by human cytomegalovirus (HCMV) or other representatives of the Herpesviridae group.
[0108] A further aspect of the present invention relates to the use of a pharmaceutical composition according to the invention in a method for the treatment and / or prevention of diseases, preferably viral infections, in particular infections caused by human cytomegalovirus (HCMV) or other representatives of the Herpesviridae group.
[0109] Another aspect of the present invention relates to the use of a pharmaceutical composition according to the present invention for the preparation of a medicament for the treatment and / or prevention of a disease, in particular a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group.
[0110] Yet another aspect of the present invention relates to a method for treating and / or preventing a viral infection, preferably a human cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group, in a subject in need thereof by administering a pharmaceutical composition according to the present invention, in one embodiment said subject is selected from the group consisting of newborns, subjects in need of a particular solid organ transplant, e.g. subjects with impaired kidneys and subjects in need of an allogeneic hematopoietic stem cell transplant.
[0111] In general, it has proven advantageous to administer the pharmaceutical composition in such a way that about 0.001 to 10 mg of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid (letermovir) is administered per kg of body weight, preferably 0.01 to 5 mg per kg.
[0112] Nevertheless, it may be necessary to deviate from the aforementioned amount of letermovir, depending, inter alia, on body weight, individual response to the active substance, and the time and interval at which it is administered.For example, in certain cases, it may be sufficient to administer less than the aforementioned minimum amount of letermovir, while in other cases the upper limit described may be exceeded.When administering larger amounts, it may be advisable to divide them into several individual doses per day.
[0113] The present invention will now be described in detail with reference to non-limiting examples.
[0114] Unless otherwise stated, the percentages given in the following tests and examples are percentages by weight, the parts are parts by weight and the solvent ratios, dilution ratios and concentrations of liquid solutions are in each case related to volume.
[0115] Abbreviation API API h time HCl Hydrochloric acid HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HPBCD Hydroxypropyl-β-cyclodextrin HPLC High Pressure Liquid Chromatography conc. concentration min. LAF laminar flow PEG Polyethylene glycol PDE daily exposure allowance R T Retention time (in HPLC) RP-HPLC Reversed Phase High Pressure Liquid Chromatography rpm revolutions per minute rt room temperature
[0116] Analysis method Visual inspection Samples were gently manually radially agitated in front of a white background for 5 seconds and inspected for the presence of visible particles.
[0117] pH The pH values of the samples were measured using a calibrated pH meter EUTEGH CAKTON PH / Ion 510 serial number 172361 with a Polilyte lab electrode. The sample was stirred and the electrode was introduced. Measurements were taken until the pH value stabilized. The electrode was thoroughly rinsed with water between measurements. pH measurements were performed with an analytical volume of ~1-2 mL and at a specified temperature of 22°C ± 3°C. A three-point correction of the pH meter was performed daily using buffers of pH 7.00, pH 4.01 and pH 10.01 (Hamilton Duracal buffer).
[0118] Reversed-phase high-performance liquid chromatography (RP-HPLC) RP-HPLC was used to measure the concentrations of letermovir free base and possible degradation products.
[0119] Table 1 shows an overview of the eluents used in the RP-HPLC analysis. [Table 1]
[0120] The following parameters were used for the RP-HPLC method: Instrumentation: Agilent Technologies 1200 Series with VWD G131413 detector Column: Agilent Zorbax Eclipse XDB C-18, 150×4.6mm, 5μm Flow rate: 1.0ml / min Solvent A: 0.1% formic acid in water Solvent B: 0.1% formic acid in 100% methanol End time: 26 minutes Injection volume: 10μl Column temperature: 35℃ Wavelength: 260nm
[0121] The gradient used for the RP-HPLC method is shown in Table 2. [Table 2]
[0122] A calibration curve of the reference standard was used to quantitate letermovir free base in solution.
[0123] Samples were diluted to approximately 2 mg / mL in water (corrected for letermovir free base in solution) and analyzed with an injection volume of 10 μl. Prior to injection, diluted samples were filtered through a syringe filter (nylon, 0.45 μm).
[0124] Peak integration was performed manually for all API related peaks. Peaks that were also present in the blank or formulation buffer injections were ignored.
[0125] Powder X-ray Diffraction (PXRD) Equipment: Powder diffraction patterns were acquired in transmission geometry on a Bruker D8 Advance Series 2 Theta / Theta powder diffraction system using CuKα1 radiation. The system was equipped with a VÅNTEC-1 single photon counting PSD, a germanium monochromator, a fixed divergence slit and a radial solar. Software used: Data collection with DIFFRAC and XRD Commander V.2.5.1 and evaluation with EVA V.5.0.0.22 (Bruker-AXS 2010-2018).
[0126] Sample preparation: Approximately 15 mg of raw sample was prepared in a standard sample holder using two foils of polyacetate.
[0127] Measurement conditions: The samples were measured in the 2θ range of 4° to 40° at room temperature for a 0.1 hour measurement with an angle step of 0.049° and a time per step of 2787 seconds. EXAMPLES
[0128] Example 1. Solubility and pH studies of solutions of different Letermovir forms and solutions of Letermovir free base containing different equivalent amounts of NaOH To account for differences in pH immediately after dissolution and after one week, and to examine the effect on precipitation and solubility, a first set of letermovir samples was prepared by dissolving letermovir free base, letermovir sodium salt amorphous, letermovir sodium salt trihydrate, or letermovir sodium salt monohydrate in water to prepare solutions with concentrations of 20 mg / mL and 100 mg / mL for letermovir free base.
[0129] A second set of samples was prepared by adding different equivalents of sodium hydroxide (0.84, 0.86, 0.88, and 0.9 equivalents) to the letermovir free base solution, and for comparison, a blank solution was also prepared containing the same amount of water and sodium hydroxide equivalents but no letermovir.
[0130] Letermovir free base and letermovir sodium salt amorphous were dried overnight in a vacuum oven at 90° C. (approximately 5 mbar) to remove residual water.
[0131] a) Initial drying Procedure: Two samples of letermovir sodium amorphous and ten samples of letermovir free base were prepared by weighing the corresponding materials and drying overnight at 90°C (~5 mbar) in a vacuum oven to remove residual water and avoid weighing errors, and the equivalent amount of NaOH was calculated (Table 3).
[0132] Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare solutions with concentrations of 20 mg / mL and 100 mg / mL for letermovir free base. [Table 3]
[0133] b) Preparation of suspensions / solutions and analysis of pH and solubility Procedure: A corresponding amount of water was added to each sample and the respective equivalent amount of 1M NaOH aqueous solution was further added to the second set of samples (Table 4, Table 5 and Table 6). No NaOH was added to the first set of samples. The suspensions were stirred at room temperature and the pH was measured immediately after preparation and after one week. The effect on solubility and precipitation was also investigated (Table 7, Table 8 and Table 9). [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9]
[0134] result The pH values of solutions of letermovir sodium salt (dalt) trihydrate, letermovir sodium salt monohydrate, and letermovir sodium salt amorphous in water were consistently between 9 and 9.5. After one week, no significant differences were observed. The solutions were completely clear with no effect on precipitation over time as judged by visual inspection. The pH of a suspension of letermovir free base in water without sodium hydroxide was approximately 6. The suspension did not dissolve even after one week.
[0135] The pH of solutions of letermovir free base in water containing different equivalents of sodium hydroxide (0.84 to 0.9 equivalents) was approximately 7.8. Only a small amount of particles were observed in the air-water interface after 24 hours.
[0136] A blank solution prepared without letermovir free base and using only sodium hydroxide was clear and had a pH of approximately 12.5.
[0137] Example 2. Observation of solutions of Letermovir free base with different equivalent amounts of sodium hydroxide at different temperatures a) Initial drying Twenty-six samples of letermovir free base were prepared by weighing the material and drying overnight at 90° C. (approximately 5 mbar) in a vacuum oven to remove residual water and avoid weighing errors, and the equivalent amount of NaOH was calculated (Table 10).
[0138] Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions. [Table 10]
[0139] b) Preparation of suspensions / solutions and analysis of pH and solubility Procedure: The corresponding amount of water and the respective equivalent amount of 1M NaOH aqueous solution were added to each sample. The suspensions were stirred at room temperature, 40°C or 60°C, respectively. The pH, solubility and precipitation were observed after 12 hours, 24 hours, 48 hours and 7 days (Table 11, Table 12, Table 13 and Table 14). [Table 11] [Table 12] [Table 13] [Table 14]
[0140] result The 100 mg / mL sample held at 60°C turned into a clear colored solution as judged by visual inspection, which was further analyzed by HPLC. No other additional signals were observed. A 20 μL sample was diluted with 1 mL of water to obtain a concentration of 2 mg / mL, followed by HPLC analysis.
[0141] Samples of 20 mg / mL letermovir free base containing 0.8 and 0.82 equivalents of sodium hydroxide contained particles in suspension. Increased solubility was observed with increasing equivalents of sodium hydroxide, and after 2 hours the sample was nearly completely dissolved (only a few particles were seen in the air-water phase).
[0142] All samples of 100 mg / mL letermovir free base were nearly completely dissolved (only a few particles were visible in the air-water phase).
[0143] By increasing the temperature, the following effects were observed: 40℃ A sample of 20 mg / mL letermovir free base with -0.84 equivalents of NaOH contained particles in suspension. Samples of 20 mg / mL and 100 mg / mL letermovir free base containing -0.86 and 0.88 equivalents of NaOH were clear solutions after 1 week. A sample of 100 mg / mL letermovir free base containing -0.84 equivalents of NaOH was a clear solution after 1 week. 60℃ A sample of 20 mg / mL letermovir free base containing -0.84 equivalents of NaOH was a cloudy suspension. A sample of 20 mg / mL letermovir free base containing -0.86 equivalents of NaOH contained particles in suspension even after one week. A sample of 20 mg / mL letermovir free base containing -0.88 equivalents of NaOH was a clear solution after 1 week. Samples of 100 mg / mL letermovir free base containing -0.84, 0.86, and 0.88 equivalents of NaOH were clear but colored solutions after one week.
[0144] Example 3. Freeze-drying after 7 days and redissolution in water a) Initial drying Fourteen samples of letermovir free base were prepared by weighing the material and drying overnight at 90° C. (approximately 5 mbar) in a vacuum oven to remove residual water and avoid weighing errors, and the equivalent amount of NaOH was calculated (Table 15).
[0145] Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions. [Table 15]
[0146] b) Preparation of suspensions / solutions and analysis of solubility Procedure: A corresponding amount of water and the respective equivalent of 1M NaOH aqueous solution were added to each sample. The suspensions were stirred at room temperature and the effect on solubility and precipitation was examined (Table 16). [Table 16]
[0147] Solubility over 7 days After 24 hours, all samples still had some precipitate. After 48 hours, precipitate remained in the 20 mg / mL samples containing 0.8 and 0.82 equivalents of NaOH. In the other samples, only a small amount of solid was seen in the air-water phase.
[0148] After one week, precipitate remained in the 20 mg / mL samples containing 0.8 and 0.82 equivalents of NaOH, and only a small amount of solid was seen in the air-water phase in the 20 mg / mL sample containing 0.84 equivalents of NaOH.
[0149] The remaining samples were clear solutions after one week as determined by visual inspection.
[0150] c) Lyophilization and reconstitution in water After one week, the samples were freeze-dried.
[0151] procedure: 20 mg / mL sample: 3 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 3 mL of water and the precipitation and pH were checked (Table 17).
[0152] 100 mg / mL sample: 2.6 mL aliquots were placed in a freezer for 2 hours. Liquid nitrogen was used to freeze the samples and the lyophilization process was carried out over 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 13 mL of water and the precipitation and pH were checked (Table 17). [Table 17]
[0153] Example 4. Freeze-drying after 7 days and reconstitution in lactated Ringer's solution a) Initial drying Fourteen samples of letermovir free base were prepared by weighing the material, removing residual water, and drying overnight in a vacuum oven at 90° C. (approximately 5 mbar) to avoid weighing errors, and the equivalent amount of NaOH was calculated (Table 18).
[0154] Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions. [Table 18]
[0155] b) Preparation of suspensions / solutions and analysis of solubility Procedure: A corresponding amount of water and the respective equivalent of 1M NaOH aqueous solution were added to each sample. The suspensions were stirred at room temperature and the effect on solubility and precipitation was examined (Table 19). [Table 19]
[0156] Solubility over 7 days After 24 hours, all samples still had some precipitate. After 48 hours, precipitate remained in the 20 mg / mL samples containing 0.8 and 0.82 equivalents of NaOH. In the other samples, only a small amount of solid was seen in the air-water phase.
[0157] After one week, precipitate remained in the 20 mg / mL samples containing 0.8 and 0.82 equivalents of NaOH, and only a small amount of solid was seen in the air-water phase in the 20 mg / mL sample containing 0.84 equivalents of NaOH.
[0158] The other samples had clear solutions after one week as determined by visual inspection.
[0159] c) Lyophilization and reconstitution in lactated Ringer's solution After one week, the samples were freeze-dried.
[0160] procedure: 20 mg / mL sample: 3 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 3 mL of lactated Ringer's solution and the precipitation and pH were checked (Table 20).
[0161] 100 mg / mL sample: 2.6 mL aliquots were placed in a freezer for 2 hours. Liquid nitrogen was used to freeze the samples and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 13 mL of lactated Ringer's solution and the precipitation and pH were checked (Table 20). [Table 20]
[0162] Example 5. Freeze-drying after 7 days and reconstitution in 5% aqueous glucose solution a) Initial drying Fourteen samples of letermovir free base were prepared by weighing the material, removing residual water, and drying overnight in a vacuum oven at 90° C. (approximately 5 mbar) to avoid weighing errors, and the equivalent amount of NaOH was calculated (Table 21).
[0163] Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions. [Table 21]
[0164] b) Preparation of suspensions / solutions and analysis of solubility Procedure: A corresponding amount of water and the respective equivalent of 1M NaOH aqueous solution were added to each sample. The suspensions were stirred at room temperature and the effect on solubility and precipitation was examined (Table 22). [Table 22]
[0165] Solubility over 7 days After 24 hours, all samples still had some precipitate. After 48 hours, precipitate remained in the 20 mg / mL samples containing 0.8 and 0.82 equivalents of NaOH. In the other samples, only a small amount of solid was seen in the air-water phase.
[0166] After one week, precipitate remained in the 20 mg / mL samples containing 0.8 and 0.82 equivalents of NaOH, whereas in the 20 mg / mL sample containing 0.84 equivalents of NaOH, a small amount of solid was only found in the air-water phase.
[0167] The other samples had clear solutions after one week as determined by visual inspection.
[0168] c) Freeze-drying and reconstitution in a 5% aqueous glucose solution After one week, the samples were freeze-dried.
[0169] procedure: 20 mg / mL sample: 3 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 3 mL of 5% glucose solution and the precipitation and pH were checked (Table 23).
[0170] 100 mg / mL sample: 2.6 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 100 mg / mL, the resulting solid was dissolved with about 13 mL of 5% glucose solution and the precipitation and pH were checked (Table 23). [Table 23]
[0171] summary Lyophilized samples (initial concentrations of 20 mg / mL and 100 mg / mL) were completely soluble upon reconstitution to 20 mg / mL in water and lactated Ringer's solution. Samples with an initial concentration of 20 mg / mL and 0.8 or 0.82 equivalents of NaOH formed cloudy suspensions when a 5% glucose solution was used.
[0172] Example 6. Solubility and pH studies of Letermovir free base containing 0.6 to 0.78 NaOH equivalents relative to Letermovir free base A series of samples was prepared by adding different molar equivalents (0.60, 0.62, 0.64, 0.66, 0.68, 0.70, 0.72, 0.74, 0.76, 0.78) of sodium hydroxide to the letermovir free base solution.
[0173] The letermovir free base was dried overnight in a vacuum oven at 90° C. (approximately 5 mbar) to remove residual water.
[0174] a) Initial drying Procedure: 22 samples of letermovir free base were prepared by weighing the corresponding material and drying overnight at 90°C (~5 mbar) in a vacuum oven to remove residual water and avoid weighing errors, and the equivalent amount of NaOH was calculated (Table 24).
[0175] Samples of letermovir free base were dissolved in 7.5 mL and 5 mL, respectively, to prepare solutions with concentrations of 20 mg / mL and 100 mg / mL for letermovir free base. [Table 24]
[0176] b) Preparation of suspensions / solutions and analysis of pH and solubility Procedure: 1N standard solutions of NaOH and water were prepared (final volumes 7.5mL and 5mL). Alkalizing solution was added to the solid. The suspension was stirred at room temperature until the solid was completely dissolved. Samples were filled up with water to the target volume of 7.5mL and 5mL to achieve the desired concentration of 20mg / mL or 100mg / mL respectively. The suspension was stirred at room temperature and pH, solubility and precipitation were monitored after 24 hours, 48 hours and 7 days. Temperature analysis was taken into account to determine the ambient temperature vs. solution temperature after 12 hours, 24 hours, 48 hours and 7 days. [Table 25] [Table 26]
[0177] Freeze-drying and reconstitution in water procedure: 20 mg / mL samples: 2 mL aliquots were placed in the freezer for 2 hours. The samples were frozen using liquid nitrogen and the freeze-drying process was carried out over 2 days (average vacuum approx. 0.05 mbar, temperature approx. -86°C).
[0178] A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. The resulting solid was dissolved in approximately 2 mL of water to a final concentration of 20 mg / mL and examined for precipitation and pH.
[0179] 100 mg / mL sample: 1.5 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. The resulting solid was dissolved in about 7.5 mL of water to a final concentration of 100 mg / mL and checked for precipitation and pH. [Table 27] [Table 28]
[0180] Freeze-drying and redissolution in a 5% solution of glucose in water procedure: 20 mg / mL samples: 2 mL aliquots were placed in the freezer for 2 hours. The samples were frozen using liquid nitrogen and the freeze-drying process was carried out over 2 days (average vacuum approx. 0.05 mbar, temperature approx. -86°C).
[0181] A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. The resulting solid was dissolved with approximately 2 mL of a 5% (wt / vol) solution of glucose in water to a final concentration of 20 mg / mL and examined for precipitation and pH.
[0182] 100 mg / mL samples: 1.5 mL aliquots were placed in the freezer for 2 hours. The samples were frozen using liquid nitrogen and the freeze-drying process was carried out over 2 days (average vacuum approx. 0.05 mbar, temperature approx. -86°C).
[0183] A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. The resulting solid was dissolved with approximately 7.5 mL of a 5% (wt / vol) solution of glucose in water to a final concentration of 100 mg / mL and examined for precipitation and pH. [Table 29] [Table 30]
[0184] Lyophilization and reconstitution in lactated Ringer's solution procedure: 20 mg / mL samples: 2 mL aliquots were placed in the freezer for 2 hours. The samples were frozen using liquid nitrogen and the freeze-drying process was carried out over 2 days (average vacuum approx. 0.05 mbar, temperature approx. -86°C).
[0185] A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. The resulting solid was dissolved in approximately 2 mL of lactated Ringer's solution to a final concentration of 20 mg / mL and examined for precipitation and pH.
[0186] 100 mg / mL samples: 1.5 mL aliquots were placed in the freezer for 2 hours. The samples were frozen using liquid nitrogen and the freeze-drying process was carried out over 2 days (average vacuum approx. 0.05 mbar, temperature approx. -86°C).
[0187] A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. The resulting solid was dissolved in approximately 7.5 mL of lactated Ringer's solution to a final concentration of 100 mg / mL and examined for precipitation and pH. [Table 31] [Table 32] Examples of embodiments of the present invention are listed in the following items [Aspect 1] to [Aspect 13]. [Aspect 1] A pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [ka] the sodium ion is contained in a molar ratio relative to letermovir in the range of 0.50 to <1.00:1.00, preferably 0.65 to <1.00:1.00, more preferably 0.72 to <1.00:1.00, more preferably 0.80 to <1.00:1.00, more preferably 0.80 to 0.90:1.00; the pharmaceutical composition, when dissolved in water at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD); Pharmaceutical compositions. [Aspect 2] 2. The pharmaceutical composition according to embodiment 1, further comprising at least one excipient selected from the group consisting of carbohydrates, in particular selected from sucrose and mannitol, amino acids, in particular phenylalanine, polyalkoxy compounds, in particular poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), in particular PVP PF12. [Aspect 3] 2. The pharmaceutical composition of embodiment 1, wherein the pharmaceutical composition is essentially free of complexed solubilizing agents. [Aspect 4] 3. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition comprises a polyalkoxy compound, in particular a poloxamer, more particularly poloxamer 188, and is essentially free of other complexing solubilizers. [Aspect 5] 3. The pharmaceutical composition according to aspect 2, wherein the excipient is mannitol or sucrose, or a combination thereof. [Aspect 6] 6. The pharmaceutical composition according to any one of the preceding aspects, further comprising a buffer, preferably trishydroxyaminomethane (Tris). [Aspect 7] A method for producing the pharmaceutical composition according to any one of aspects 1 to 6, comprising the steps of: i) providing a solution of letermovir and sodium ions, the molar ratio of letermovir to sodium ions being in the range of 0.50-<1.00:1.00, preferably 0.65-<1.00:1.00, more preferably 0.72-<1.00:1.00, more preferably 0.80-<1.00:1.00, more preferably 0.80-0.90:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, in particular sucrose or mannitol, amino acids, in particular phenylalanine, polyalkoxy compounds, in particular poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), in particular PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i) to a value in the range of 7-8, preferably 7.4-7.8, preferably with HCl; iii) optionally filtering the solution. A method comprising: [Aspect 8] 8. The method of embodiment 7, further comprising the subsequent additional step of lyophilizing the resulting solution to obtain a lyophilisate. [Aspect 9] The method of embodiment 8 further comprising a subsequent additional step of reconstituting the lyophilizate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 20-100 mg / mL with respect to letermovir, followed by diluting the reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, wherein the first and second parenterally acceptable diluents may be the same or different. [Aspect 10] A pharmaceutical composition according to any one of aspects 1 to 6, obtainable by the method according to any one of aspects 7 to 9. [Aspect 11] 17. The pharmaceutical composition according to any one of aspects 1 to 6 or 10 for use in a method for the treatment and / or prophylaxis of a disease, in particular a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group. [Aspect 12] 20. Use of a pharmaceutical composition according to any one of aspects 1 to 6 or 10 for the preparation of a medicinal product for the treatment and / or prevention of a disease, in particular a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group. [Aspect 13] 13. A method for the treatment and / or prevention of a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection due to another member of the Herpesviridae group, in a subject in need thereof, comprising administering said pharmaceutical composition according to any one of aspects 1 to 6 or 10.
Claims
1. A pharmaceutical composition comprising letermovir of formula (I) and sodium ions, [Formula 1] the sodium ions are in a molar ratio relative to letermovir in the range of 0.72-0.90:1.00; said pharmaceutical composition is capable of exhibiting a pH in the range of 7 to 8 when dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir; - essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin; Pharmaceutical compositions.
2. 2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises said sodium ion in a molar ratio relative to letermovir in the range of 0.80-0.90:1.
00.
3. The pharmaceutical composition according to claim 1 or 2, which is capable of exhibiting a pH in the range of 7.4 to 7.8 when dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein the pharmaceutical composition is essentially free of hydroxypropyl-β-cyclodextrin (HPBCD).
5. The pharmaceutical composition according to any one of claims 1 to 4, further comprising at least one excipient selected from the group consisting of carbohydrates, amino acids, polyalkoxy compounds, and polyvinylpyrrolidone (PVP).
6. 6. The pharmaceutical composition of claim 5, wherein the carbohydrate is sucrose or mannitol, the amino acid is phenylalanine, the polyalkoxy compound is a poloxamer, and the polyvinylpyrrolidone (PVP) is PVP PF12.
7. 7. The pharmaceutical composition of claim 6, wherein the poloxamer is poloxamer 188.
8. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition is essentially free of complexed solubilizing agents.
9. The pharmaceutical composition of any one of claims 1 to 7, wherein the pharmaceutical composition comprises a polyalkoxy compound and is essentially free of other complexing solubilizing agents.
10. The pharmaceutical composition of claim 9, wherein the polyalkoxy compound is a poloxamer.
11. 11. The pharmaceutical composition of claim 10, wherein the poloxamer is poloxamer 188.
12. The pharmaceutical composition according to any one of claims 5 to 7, wherein the excipient is mannitol or sucrose or a combination thereof.
13. The pharmaceutical composition according to any one of claims 1 to 12, further comprising a buffer.
14. 14. The pharmaceutical composition of claim 13, wherein the buffer is trishydroxyaminomethane (Tris).
15. A method for producing the pharmaceutical composition according to any one of claims 1 to 14, comprising the steps of: i) providing a solution of letermovir and sodium ions, the molar ratio of sodium ions to letermovir being in the range of 0.72-0.90:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, amino acids, polyalkoxy compounds, and polyvinylpyrrolidone (PVP); ii) if necessary, adjusting the pH of the solution obtained in step i) to a value in the range of 7 to 8; iii) optionally filtering the solution. A method comprising:
16. 16. The method of claim 15, wherein the molar ratio of sodium ions to letermovir in the solution of letermovir and sodium ions in step i) is in the range of 0.80-0.90:1.
00.
17. 17. The method of claim 15 or 16, wherein the carbohydrate is sucrose or mannitol, the amino acid is phenylalanine, the polyalkoxy compound is a poloxamer, and the polyvinylpyrrolidone (PVP) is PVP PF12.
18. 18. The method of claim 17, wherein the poloxamer is poloxamer 188.
19. The method according to any one of claims 15 to 18, further comprising a subsequent additional step of lyophilizing the obtained solution to obtain a lyophilisate.
20. 20. The method of claim 19, further comprising the subsequent additional step of reconstituting the lyophilizate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 20-100 mg / mL with respect to letermovir, followed by optionally diluting the reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, wherein the first and second parenterally acceptable diluents can be the same or different.
21. A pharmaceutical composition according to any one of claims 1 to 14 for use in a method for the treatment and / or prevention of a viral infection.
22. 22. A pharmaceutical composition for use in a method for the treatment and / or prevention of a disease according to claim 21, wherein the viral infection is a human cytomegalovirus (HCMV) infection or an infection with another member of the Herpesviridae group.
23. Use of a pharmaceutical composition according to any one of claims 1 to 14 for the preparation of a medicine for the treatment and / or prevention of a viral infection.
24. 24. The use according to claim 23, wherein the viral infection is a human cytomegalovirus (HCMV) infection or an infection with another member of the Herpesviridae group.
25. A pharmaceutical for the treatment and / or prevention of a viral infection in a subject in need thereof, comprising the pharmaceutical composition according to any one of claims 1 to 14.
26. 26. The method of claim 25, wherein the viral infection is a human cytomegalovirus (HCMV) infection or an infection with another member of the Herpesviridae group.
Citation Information
Patent Citations
Salts of dihydroquinazoline derivatives
JP2015508802A
Cited By
Pharmaceutical compositions comprising 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and sodium ions
US12714709B2
